Drug Profile


Alternative Names: Ropidoxuridine

Latest Information Update: 15 Jan 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator The Research Foundation of State University of New York; Yale University
  • Developer SuperGen
  • Class Antivirals; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Thymidine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anaplastic astrocytoma; Hepatitis B; Herpes simplex virus infections; Solid tumours

Most Recent Events

  • 09 Jan 2007 Discontinued - Phase-I for Solid tumours in USA (PO)
  • 09 Jun 2006 IPdR has received orphan drug status for malignant glioma in the US
  • 09 Jan 2006 Discontinued - Phase-II for Anaplastic astrocytoma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top